Literature DB >> 26069897

Quantitative chemical proteomics for investigating the biomarkers of dioscin against liver fibrosis caused by CCl4 in rats.

Xiaoling Zhang1, Lina Xu, Lianhong Yin, Yan Qi, Youwei Xu, Xu Han, Jinyong Peng.   

Abstract

In the present work, the effect of dioscin against liver fibrosis in rats caused by carbon tetrachloride (CCl4) was confirmed. Then, the differentially expressed proteins from rat liver were identified using two-dimensional differential in-gel electrophoresis technology. Ten new biomarkers including protein disulfide isomerase A3, selenium-binding protein 1, glutamine synthetase, senescence marker protein 30, hemopexin, keratin 8, keratin 18, vimentin, Annexin A5 and dermatopontin associated with liver fibrosis were found and validated, and new insights through affecting multiple drug targets and biological processes were also provided to reveal the mechanisms of dioscin against hepatic fibrosis for the first time.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26069897     DOI: 10.1039/c4cc09160d

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  13 in total

1.  Potent effects of dioscin against hepatocellular carcinoma through regulating TP53-induced glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis, autophagy, and DNA damage.

Authors:  Zhang Mao; Xu Han; Dahong Chen; Youwei Xu; Lina Xu; Lianhong Yin; Huijun Sun; Yan Qi; Lingling Fang; Kexin Liu; Jinyong Peng
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

2.  Dioscin ameliorates peritoneal fibrosis by inhibiting epithelial-to-mesenchymal transition of human peritoneal mesothelial cells via the TLR4/MyD88/NF-κB signaling pathway.

Authors:  Qiuyuan Shao; Chunming Jiang; Yangyang Xia; Min Zhao; Qingyan Zhang; Bo Jin; Jin Liu
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

3.  Chlorogenic Acid Inhibits Liver Fibrosis by Blocking the miR-21-Regulated TGF-β1/Smad7 Signaling Pathway in Vitro and in Vivo.

Authors:  Fan Yang; Lei Luo; Zhi-De Zhu; Xuan Zhou; Yao Wang; Juan Xue; Juan Zhang; Xin Cai; Zhi-Lin Chen; Qian Ma; Yun-Fei Chen; Yu-Jie Wang; Ying-Ying Luo; Pan Liu; Lei Zhao
Journal:  Front Pharmacol       Date:  2017-12-19       Impact factor: 5.810

4.  Discovery of a Potential Plasma Protein Biomarker Panel for Acute-on-Chronic Liver Failure Induced by Hepatitis B Virus.

Authors:  Ni Zhou; Kuifeng Wang; Shanhua Fang; Xiaoyu Zhao; Tingting Huang; Huazhong Chen; Fei Yan; Yongzhi Tang; Hu Zhou; Jiansheng Zhu
Journal:  Front Physiol       Date:  2017-12-06       Impact factor: 4.566

5.  Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-β.

Authors:  Xufeng Tao; Lina Xu; Lianhong Yin; Xu Han; Yan Qi; Youwei Xu; Shasha Song; Yanyan Zhao; Jinyong Peng
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

6.  Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress.

Authors:  Lisha Zhao; Xufeng Tao; Yan Qi; Lina Xu; Lianhong Yin; Jinyong Peng
Journal:  Redox Biol       Date:  2018-03-06       Impact factor: 11.799

7.  Protective Effects of Dioscin Against Doxorubicin-Induced Hepatotoxicity Via Regulation of Sirt1/FOXO1/NF-κb Signal.

Authors:  Shasha Song; Liang Chu; Huifang Liang; Jin Chen; Junnan Liang; Zhao Huang; Bixiang Zhang; Xiaoping Chen
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

Review 8.  Personalized Medicine in Ocular Fibrosis: Myth or Future Biomarkers.

Authors:  Cynthia Yu-Wai-Man; Peng Tee Khaw
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-09-01       Impact factor: 4.730

Review 9.  Drugs and Targets in Fibrosis.

Authors:  Xiaoyi Li; Lixin Zhu; Beibei Wang; Meifei Yuan; Ruixin Zhu
Journal:  Front Pharmacol       Date:  2017-11-23       Impact factor: 5.810

10.  Oridonin ameliorates carbon tetrachloride-induced liver fibrosis in mice through inhibition of the NLRP3 inflammasome.

Authors:  Dong Liu; Hailong Qin; Bixian Yang; Bin Du; Xuelin Yun
Journal:  Drug Dev Res       Date:  2020-03-26       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.